{"name":"Clene Nanomedicine","slug":"clene-nanomedicine","ticker":"","exchange":"","domain":"","description":"Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on the development of nanocatalytic gold therapeutics for neurodegenerative and neuro-inflammatory diseases. The company's lead candidates, CNMAu8 and CNM-ZnAg, are currently in Phase 2 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9vVUhIQUlKQUlnNW5EaUVQNkpOdHh6TFZQRnJjbEJRQnEwTVhfOWpMUFJHSXhrQ0UzMjBhaGhkTGlRdnd0NklSb3RqenFoOVZjMDBPZzZCMW85NU5ZcUxBdTl2Nm1wbmtqMmFhYWV3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Clene (CLNN) - Stock Titan","headline":"If You Invested $1,000 in Clene (CLNN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-29","type":"pipeline","source":"simplywall.st","summary":"Clene Inc. (NASDAQ:CLNN): When Will It Breakeven? - simplywall.st","headline":"Clene Inc. (NASDAQ:CLNN): When Will It Breakeven?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQYmtyV3JOSE1tU19HWE1HQzgwRVhwYkJNUG1iLS1lQmtONW9BNGhFWDFUNmJVVW1ObU5ZYjhBZHExaDg5bjdtZjRvbERUbFdwVWU2NFZNWDdxbG1VVnVtZzFZUTMwa3d5UkMxZndxYWE5dHpNanJwUi1uTThCei1QNDhmX0JPWHhONV90bmhSazMtX1lDb0pzN2NRbTBpaUVoRTVBYXg3YkZ3SHVlZnRIZXVaRUtDZGNmUFlpTkpVY0hSSF80RjhKMVFUTVctelBNMGEtZVJTbk40Z251Vy13akJRRktuNU5qN3BrdjZmVlFHVnl4YnFNQ251cmc1Z01ha1M0REdKX29rYU02dFE?oc=5","date":"2025-07-24","type":"pipeline","source":"PR Newswire UK","summary":"CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight - PR Newswire UK","headline":"CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1NMUhva2Z3anY2OEZVM1RKd3BXaWdOVUVtSjNKeVlZV3YwR2JweXlOQVRscVU4YzV6ODQ1Si1GYnNVRFR6SUNiS1l3VGNVdkxJWl90ZDFmZmJZLVNoSE1HdGdLNk9UWC1YZm5XZ2pkQTE2cFNCZ2NaRmxQLVo?oc=5","date":"2025-06-25","type":"pipeline","source":"Pharma Voice","summary":"After myriad failures, a new wave of ALS drugs approaches - Pharma Voice","headline":"After myriad failures, a new wave of ALS drugs approaches","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOWVl6azE1R1BhS3hhdkM1ZmFLUm5qOWhJRWZXTF9PbEVQNW9peEY3elVqTUpFVzltUWVBcjd1SXhybTVRWUlmV2g4UER0LU1wSkdhdW1DZHNLb0pkUHFWYnc2WndtY0FGQUowek1qUEVONnkxYXJzbFNhX0MtVVZqVGdwUU9iSDFWOU5nUUJqSmxmQllKWDFnNA?oc=5","date":"2025-02-27","type":"regulatory","source":"ALS News Today","summary":"New analyses in ALS planned to aid CNM-Au8’s accelerated approval - ALS News Today","headline":"New analyses in ALS planned to aid CNM-Au8’s accelerated approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPeXg0RGlIbkhKRmxyWVpwdnRYSzVFdFFVcWtuelBwSTRMN3NsRFh6VkxXSnZQcmRzUndmLTkwaWRDUUl3QmZmMENaYUQ1OFhtclktMjcxQmcxMVlWdXFvQ29SSlVzWm9yQU1fcFYxeVkwaE1Hai1pTGx1ZzFuYUZBSXZramQyN00?oc=5","date":"2025-02-18","type":"trial","source":"pharmaphorum","summary":"Four more drugs in keenly watched ALS trial miss the mark - pharmaphorum","headline":"Four more drugs in keenly watched ALS trial miss the mark","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNYVZGb1d4SlV6bHhTQ0RSVURidk9lekxZR0JyZlM1OEFCcmNBcnpaNGZCZzdybERwZFNjb2VSSjJmWXJpdUMwbWMxZW93ZXY0SV8wUDRBSVRaaFRxeFpPNXFCZ3JqQUpwbEtWdFNEY2lPYURISVF2QmV4aG8zdmw0dlpxV0RFT3VnV29fRmdkdDd3WkVrM1VJaU5rb0J3aHdGbkhGeE0yRFM4clBOQWxGT0JaTFcxS3VlVHZzNHU1YjlhQlEtcG1OUjlzdEp1QjU5RlNBeXNlcHZJLVl6SVBONkdkTQ?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire","headline":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPSzVKN3AwM25RZkRwenJKb3pnVlFCVXhpQnUtQ3ZNcFFaVnA2UEg5SFpUQ3FscTdWS2JRZTdNUVBkeE1YLXBFVFRmV3dwbVNQV2F2SExsUVI2RE5GekUzVmVQb0p0Mm9OMmNKdWNMR3QzTk9SUzNtUXk3NkRZUktCM1ZDMWZjLXBNZmdvR0gwZUd6T1dsNXhneXdEMms?oc=5","date":"2024-09-02","type":"pipeline","source":"Fortune Business Insights","summary":"Amyotrophic Lateral Sclerosis Therapeutics Market Size, 2034 - Fortune Business Insights","headline":"Amyotrophic Lateral Sclerosis Therapeutics Market Size, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOZ3F3TTdtOE1JeWZ3M2EwZmpQczlLWXpKZFdKUzQzRDlZTkRUbE1iT0lYX0dBNmN4SXA1UUt6clB1R3dPak9PR3k2VS1VX0tQQjJCZFc2Q1lkaEJXODkyNDEtZXdQMi1kYVoxSVJJeU11YjJoc0JsYkJkbTRkQlNhM2hBRHNyY3RNWFhJR1dZZlZSOVFaalZXTkhQLVZXRGtILTVOUkxSOA?oc=5","date":"2024-03-26","type":"pipeline","source":"InvestorPlace","summary":"3 Penny Stocks That Could Be Multibaggers in the Making: March Edition - InvestorPlace","headline":"3 Penny Stocks That Could Be Multibaggers in the Making: March Edition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQS0NxR19RaVRRa2NxclIwakNHUnJGNlBaX1g2c1ZFMHhzUm9RdVJvb21VN0tScDI5QXpfeDE5dFM3Tm8tYXNwT1g2c2FJQjh0U3I1ZVZ5SUdRRWFFeE1aYzlscm9GZDg1TlFOMUV3TjNrSmdwT0gzUE1WRm5kMWlJYw?oc=5","date":"2023-12-21","type":"regulatory","source":"BioPharma Dive","summary":"Clene says its ALS drug data is not yet enough for FDA - BioPharma Dive","headline":"Clene says its ALS drug data is not yet enough for FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQSXZFcTg0MFdRa2VnazdseHNJUlVVY2tWaTVvRV9uSDBkSUFreWtkYlR2TGpDVC1tUHVFSERvbVl4aTQydDA2WWhGUG1LZE1LZVJzVGVjZGNXZEpDVkl3RVRWLTIyWjNVSDByQWgyWVJvRENKQ0hIMDBHdGRnOWlxbXV2akYwbUoxSW5adW92UWphdDhZanFtV3JBNHZLNDd1TW93MDZEbHZkMzlRUDg5YnBTZWdsdTlkanBwczM3N2g3TjZBU2c?oc=5","date":"2023-12-21","type":"regulatory","source":"Reuters","summary":"Clene says FDA finds ALS drug data not enough for accelerated nod - Reuters","headline":"Clene says FDA finds ALS drug data not enough for accelerated nod","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTHZWMlg0NXZoYy1EZG9EVENHMTBNdlFWRXQwUVBLU0U1aS00a3dlTHo0RGEwUHFodll6ZWg2aUUyNjRMeTY2ZlpzamRxSWVLWlYwXzNZSVk4THJIcVU0ZVFrUm5xSmNBRkFwSUNENlpPdUdfUUY4NDQ3emNmTGMyS1pmYWhBT2FnNndyaEhPRm1VRzFOT0YxLVNTOFU5WXE3TEtHUGN5aGk?oc=5","date":"2023-10-13","type":"pipeline","source":"Pharmaceutical Executive","summary":"An Evolving ‘Opinion’ Landscape: New Paths—and Synergies—for Pharma KOLs & DOLs - Pharmaceutical Executive","headline":"An Evolving ‘Opinion’ Landscape: New Paths—and Synergies—for Pharma KOLs & DOLs","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}